The most effective and physiological way to treat hyperglycemia is to restore beta-cell function and to rescue production of endogenous insulin. Increasing evidence suggests that both type 1 and type 2 diabetes are characterized by a significant defect in beta-cell mass, leading to the manifestation of the disease. Novel alternative approaches are needed to spare and expand beta-cell mass in patients with diabetes. This review sets out to describe the latest findings on how to restore the beta-cell mass and function in both forms of diabetes to modulate their progression.
Next-gen therapeutics to spare and expand beta-cell mass / A.M. Bolla, V. Usuelli, M. Ben Nasr, S. Frigerio, C. Loretelli, F. D'Addio, P. Fiorina. - In: CURRENT OPINION IN PHARMACOLOGY. - ISSN 1471-4892. - 61(2021 Dec), pp. 77-82. [10.1016/j.coph.2021.09.001]
Next-gen therapeutics to spare and expand beta-cell mass
V. Usuelli;M. Ben Nasr;S. Frigerio;C. Loretelli;F. D'Addio;P. Fiorina
2021
Abstract
The most effective and physiological way to treat hyperglycemia is to restore beta-cell function and to rescue production of endogenous insulin. Increasing evidence suggests that both type 1 and type 2 diabetes are characterized by a significant defect in beta-cell mass, leading to the manifestation of the disease. Novel alternative approaches are needed to spare and expand beta-cell mass in patients with diabetes. This review sets out to describe the latest findings on how to restore the beta-cell mass and function in both forms of diabetes to modulate their progression.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Next-gen therapeutics to spare and expand beta-cellmass.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
360.93 kB
Formato
Adobe PDF
|
360.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
